Fig. 5: Effects of MeCP2-HDO on dopaminergic neurotoxicity in MPTP-treated mice.
From: Regulation of BDNF transcription by Nrf2 and MeCP2 ameliorates MPTP-induced neurotoxicity
A Schedule of treatment, behavioral test and collection of samples. B The schematic diagram of the ICV injection of MeCP2-HDO in the brain. C MeCP2-HDO reversed the decreased time of rotarod time in MPTP-treated mice. Data are shown as mean ± SEM (n = 10). *P < 0.05; **P < 0.01 (one-way ANOVA: F2,29 = 4.452, P = 0.021). D The immunofluorescence staining for TH in the SNc of the mice treated with MeCP2-HDO or/and MPTP and quantification of the TH staining. Data are shown as mean ± SEM (n = 4). **P < 0.01 (one-way ANOVA: F2,11 = 14.083, P = 0.002). Scale bar = 50 μm. E The immunofluorescence staining for CD11b in the SNc of the mice treated with MeCP2-HDO or/and MPTP and quantification of the CD11b staining. Data are shown as mean ± SEM (n = 4). **P < 0.01 (one-way ANOVA: F2,11 = 13.573, P = 0.002). Scale bar = 50 μm. F The immunofluorescence staining for GFAP in the SNc of the mice treated with MeCP2-HDO or/and MPTP and quantification of the GFAP staining. Data are shown as mean ± SEM (n = 4). **P < 0.01 (one-way ANOVA: F2,11 = 12.309, P = 0.003). Scale bar = 50 μm. G Effects of MeCP2-HDO on the levels of Nrf2, MeCP2, and BDNF expression in the SNc of MPTP-treated mice. Data are shown as mean ± SEM (n = 7 or 8). *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA: Nrf2: F2,23 = 11.961, P < 0.001, MeCP2: F2,22 = 7.717, P = 0.003, BDNF: F2,23 = 3.674, P = 0.043). H The ChIP-PCR analysis in the MeCP2-HDO or/and MPTP-treated mice. The binding affinity of MeCP2-HDO for Nrf2 and Bdnf I promoter and MeCP2 for Bdnf IV promoter in the SNc of MPTP-treated mice. Data are shown as mean ± SEM (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA: Nrf2: F2,11 = 13.680, P = 0.002, MeCP2: F2,11 = 26.494, P < 0.001).
